DexCom (DXCM) is under the spotlight after several class action lawsuits were filed claiming the company made unauthorized changes to its G6 and G7 glucose monitoring devices. These changes could ...

A software defect could cause the app to terminate, resulting in missed alerts or alarms. Dexcom required users to download ...

Dexcom has issued a Class I recall for its G6 Android app due to crashes that could cause users to miss critical glucose ...

Dexcom's solid third-quarter report was overshadowed Friday by its "surprisingly cautious" outlook, and Dexcom stock tumbled.

Shares of DexCom Inc. slipped 5.21% to $55.00 Friday, on what proved to be an all-around favorable trading session for the ...

DexCom's third quarter was met with a negative market reaction despite outpacing Wall Street’s revenue and adjusted EPS ...

DexCom DXCM shares soared 6.5% in the last trading session to close at $106.88. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the ...

DexCom (NASDAQ:DXCM) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below provides a snapshot of their recent ratings, ...

DexCom has enormous runway for growth, not just in its home market - the U.S., but internationally as well. Manufacturing efficiencies could support their international ambitions while supporting ...

DexCom posts Q3 revenue of $1.21 billion, beating estimates and raising 2025 guidance as analysts expect strong sales and margin improvement ahead.

Thinking about buying or holding DexCom stock? You’re not alone. Whether you’re a long-term investor or just looking for a timely healthcare pick, DexCom probably caught your attention for its role in ...